High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
June 26 (Reuters) - Futures tied to the tech-heavy Nasdaq led Wall Street losses on Friday, as chip stocks came under renewed pressure after a sharp rally in the previous session, while some megacap
It's not just a "pandemic stock," after all.
The FDA’s Vaccines and Related Biological Products Advisory Committee has unanimously backed Moderna’s mRNA-based flu shot, mFlusiva, for adults 50 and older, after phase 3 data showed it to be about 27% more effective than a standard flu vaccine. This endorsement positions Moderna’s mRNA platform for a potential second major commercial use beyond COVID-19, expanding its role in routine respiratory vaccination for older adults. We’ll now explore how this unanimous FDA panel support for...
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
Shares of the vaccine maker have been on a hot streak, most recently catalyzed by a positive update from the FDA.
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups.
The company's pending vaccine approvals could help the stock continue its rise.
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
Jefferies noted that FDA decisions aligned with advisory committee recommendations 84% of the time between 2020 and 2025.
Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech’s proposed new flu shot for people 50 and older. The FDA had initially declined to consider Moderna’s application for the shot’s approval, but then agreed to review it after Moderna amended it. The advisory committee vote in favor of the vaccine isn’t binding, but the FDA generally follows such recommendations.
Moderna said an advisory committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 and older.
Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and investors questioned whether Moderna could develop a stable business beyond one historic product ...
Moderna (NASDAQ:MRNA) shares moved higher on Thursday, building on the previous session’s strong gains as investors focused on a key review of the company’s influenza vaccine by a U. S.
The Morning Bull - US Market Morning Update Thursday, Jun, 18 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.1%, as investors weigh stubborn trade price pressures against a steady Federal Reserve. Import prices for May rose 1.9%, with fuel and lubricants jumping 12.5%, which means businesses are facing higher costs on what they buy from overseas. Export prices climbed 1.3%, the sixth straight monthly rise, hinting that US goods sold...
They haven't peaked yet.
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Making Investors Richer. Moderna extended its winning streak to a fifth consecutive day on Wednesday, climbing 11.55 percent to end at $61.80 apiece, as investors loaded their portfolios ahead of its Investor Day. In a notice, Moderna Inc. (NASDAQ:MRNA) said that it will host an Investor […]
(Updates with index/price moves, FedWatch outlook, macro data, and political/company news from the f
US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve ann
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and
Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.
Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
